Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension

European Respiratory Journal 2026

View at publisher
Authors: Yogesh N. V. Reddy, Robert P. Frantz, William R. Miranda, Revati Varma, Paul M. Hassoun, Anna R. Hemnes, E. Horn, Jane A. Leopold, Franz Rischard, Erika B. Rosenzweig, Nicholas S. Hill, Serpil C. Erzurum
+10 more Gerald J. Beck, Samar Farha, J. Emanuel Finet, Christine Jellis, Deborah Kwon, Stephen Mathai, Margaret Park, W. H. Wilson Tang, Barry A Borlaug, the PVDOMICS Study Group
DOI: 10.1183/13993003.01871-2025
Cited by: 4

Abstract

BACKGROUND: Pulmonary vasodilators increase cardiac output (CO) in group 1 pulmonary hypertension (PH) and can cause high CO with unclear implications. Our objective was to describe the pathophysiology of high CO in group 1 PH. METHODS: ). RESULTS: 33%, respectively; p=0.0008), with progressively lower pulmonary vascular resistance (p

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Hemodynamic Monitoring and Therapy Heart Failure Treatment and Management

Publication details

Journal / source
European Respiratory Journal
Publisher
European Respiratory Society (ERS)
Volume
67
Issue
6
Pages
2501871–2501871
Publication date
19 February 2026
Language
EN